(BMS-936557) for Ulcerative Colitis
Inflammatory bowel disease ORIGINAL ARTICLE Gut: first published as 10.1136/gutjnl-2012-303424 on 5 March 2013. Downloaded from Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study Lloyd Mayer,1 William J Sandborn,2 Yuriy Stepanov,3 Karel Geboes,4 Robert Hardi,5 Michael Yellin,6 Xiaolu Tao,7 Li An Xu,7 Luisa Salter-Cid,7 Sheila Gujrathi,7 Richard Aranda,7 Allison Y Luo7 ▸ Additional material is ABSTRACT published online only. To view Objective Interferon-γ-inducible protein-10 (IP-10 or Significance of this study please visit the journal online fl (http://dx.doi.org/10.1136/ CXCL10) plays a role in in ammatory cell migration and gutjnl-2012-303424). epithelial cell survival and migration. It is expressed in higher levels in the colonic tissue and plasma of patients 1Immunology Institute, Mount What is already known on this subject? Sinai School of Medicine, with ulcerative colitis (UC). This phase II study assessed ▸ Ulcerative colitis (UC) is a chronic, New York, New York, USA the efficacy and safety of BMS-936557, a fully human, inflammatory disease of the colonic mucosa 2 Division of Gastroenterology, monoclonal antibody to IP-10, in the treatment of caused, in part, by an aberrant immune system. University of California San moderately-to-severely active UC. ▸ Current treatments achieve remission in a Diego, La Jolla, California, USA 3Dnipropetrovsk State Medical Design In this 8-week, phase II, double-blind, relatively small proportion of patients and can Academy, Dnipropetrovsk, multicentre, randomised study, patients with active UC be associated with toxicities, such as infections Ukraine received placebo or BMS-936557 (10 mg/kg) and malignancies.
[Show full text]